Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLUNASDAQ:CPRXNASDAQ:GDRXNASDAQ:LIFW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsCPRXCatalyst Pharmaceuticals$22.07-0.2%$23.91$14.75▼$26.58$2.70B0.721.10 million shs1.16 million shsGDRXGoodRx$5.07+8.1%$4.29$3.68▼$9.26$1.68B1.161.41 million shs2.37 million shsLIFWMSP Recovery$1.27-8.6%$1.40$1.43▼$14.55$8.33M-2.38650,933 shs36,445 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CPRXCatalyst Pharmaceuticals-0.23%-4.95%-9.88%-12.25%+43.40%GDRXGoodRx+8.10%+15.49%+35.56%+11.67%-33.46%LIFWMSP Recovery0.00%-11.19%-14.19%-2.31%-89.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACPRXCatalyst Pharmaceuticals4.9293 of 5 stars3.62.00.03.93.43.33.8GDRXGoodRx3.3946 of 5 stars3.32.00.00.03.32.51.9LIFWMSP RecoveryN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/ACPRXCatalyst Pharmaceuticals 3.25Buy$32.8348.77% UpsideGDRXGoodRx 2.64Moderate Buy$6.5529.10% UpsideLIFWMSP Recovery 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GDRX, LIFW, CPRX, and BLU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025CPRXCatalyst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025GDRXGoodRxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $5.255/9/2025GDRXGoodRxThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $5.004/29/2025GDRXGoodRxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.004/10/2025GDRXGoodRxTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.50 ➝ $5.50(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77CPRXCatalyst Pharmaceuticals$491.73M5.47$2.44 per share9.04$6.10 per share3.62GDRXGoodRx$792.32M2.29$0.34 per share14.74$1.89 per share2.68LIFWMSP Recovery$10.73M0.78$31.75 per share0.04$255.48 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/ACPRXCatalyst Pharmaceuticals$163.89M$1.5714.0610.360.9036.91%42.45%36.59%8/6/2025 (Estimated)GDRXGoodRx$16.39M$0.0863.3828.172.093.57%7.85%3.91%8/6/2025 (Estimated)LIFWMSP Recovery-$56.35M-$142.50N/A∞N/A-906.67%-6.25%-2.39%8/12/2025 (Estimated)Latest GDRX, LIFW, CPRX, and BLU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025GDRXGoodRx$0.04$0.09+$0.05$0.03$202.25 million$202.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/ACPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AGDRXGoodRxN/AN/AN/AN/AN/ALIFWMSP RecoveryN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS HealthN/A33.4233.42CPRXCatalyst PharmaceuticalsN/A6.145.96GDRXGoodRx0.745.235.23LIFWMSP Recovery0.850.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.37%CPRXCatalyst Pharmaceuticals79.22%GDRXGoodRx63.77%LIFWMSP Recovery3.77%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health24.17%CPRXCatalyst Pharmaceuticals10.40%GDRXGoodRx4.17%LIFWMSP Recovery86.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionableCPRXCatalyst Pharmaceuticals80121.97 million109.29 millionOptionableGDRXGoodRx950357.17 million342.28 millionOptionableLIFWMSP Recovery36.56 million885,000OptionableGDRX, LIFW, CPRX, and BLU HeadlinesRecent News About These CompaniesMSP Recovery, Inc.: MSP Recovery Announces Fiscal Year and Fourth Quarter 2024 Financial ResultsApril 18, 2025 | finanznachrichten.deMSP Recovery Shares Surge: $1.2B Debt Nixed In Turnaround Pact With Hazel Partners, Virage CaptialApril 11, 2025 | benzinga.comMSP Recovery reaches agreement on payment scheduleJanuary 31, 2025 | msn.comMSP: K-9 injured in drug exposure, expected to make full recoveryDecember 14, 2024 | yahoo.comThe MSP Recovery Inc Enigma: What’s Causing the Wild Swings in LIFW Stock?December 9, 2024 | bovnews.comMSP Recovery (NASDAQ:LIFW) Stock, Insider Trading ActivityDecember 7, 2024 | benzinga.comMSP Recovery, Inc. Consolidates Brand and Changes Stock Ticker to Reflect Commitment to Medicare Reimbursement SolutionsDecember 6, 2024 | quiverquant.comMSP Recovery’s (LIFW) Legal Wins Fuel Stock Surge Amid Financial StrugglesNovember 22, 2024 | bovnews.comMSP Recovery, Inc. Reports Q3 2024 EarningsNovember 19, 2024 | markets.businessinsider.comMSP Recovery Inc (LIFW) Stock Hits Another 52-week LowNovember 18, 2024 | bovnews.comMSP Recovery Inc trading halted, news pendingNovember 16, 2024 | markets.businessinsider.comWhat’s Driving MSP Recovery Inc (LIFW) Stock’s -32.22% Plunge Over the Past Month?November 14, 2024 | bovnews.comLifeWallet Announces Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comMSP Recovery announces new settlements totaling more than $5.9MNovember 12, 2024 | markets.businessinsider.comLifeWallet Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price RequirementNovember 12, 2024 | globenewswire.comLifeWallet Announces New Comprehensive Settlements Totaling More Than $5.9 Million, Continued Progress in Recoveries on Owned Claims and Acquiring Rights to Additional Claims, and Initiatives to Eliminate Wasteful Medicare Spending by Launching Beta Testing of Its Clearinghouse Solution, Built in Partnership with Palantir Technologies, Inc.November 11, 2024 | globenewswire.comInsider Purchases Worth US$732.7k See Losses As MSP Recovery Market Value Drops To US$16mNovember 6, 2024 | finance.yahoo.comMSP Recovery Inc (LIFW) Stock: Unveiling Its Hidden StrengthsNovember 4, 2024 | bovnews.comMedicaid › Medicare Secondary Payer ActNovember 2, 2024 | jdsupra.comMSP lieutenant gives update on Helene recovery in VirginiaOctober 25, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGDRX, LIFW, CPRX, and BLU Company DescriptionsBELLUS Health NASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Catalyst Pharmaceuticals NASDAQ:CPRX$22.07 -0.05 (-0.23%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$22.28 +0.22 (+0.97%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.GoodRx NASDAQ:GDRX$5.07 +0.38 (+8.10%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$5.05 -0.02 (-0.39%) As of 06/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.MSP Recovery NASDAQ:LIFW$1.27 -0.12 (-8.63%) As of 06/20/2025MSP Recovery, Inc., doing business as LifeWallet, operates as a healthcare recovery and data analytics company in the United States and Puerto Rico. The company offers claims recovery services, including services to related parties or third parties to assist entities with pursuit of claims recovery rights. It also provides LifeWallet, a scalable and expandable data ecosystem where tokenized data is stored in a platform with multiple applications, including LifeWallet EHR for hospitals, medical providers, major medical laboratories, and governmental entities that gather and store electronic health records; Chase to Pay, a real-time, or near real-time analytics driven platform that identifies the proper primary payer at the point of care; LifeChain which is in development in order to tokenize healthcare claims and patient records using blockchain technology; LifeWallet 911 which is in development for utilization by emergency service organizations; LifeWallet Legal; LifeWallet Health; and LifeWallet Sports which connected brands with college athletes. MSP Recovery, Inc. was founded in 2014 and is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
